What is it? Why is it important?

Market surveillance are activities carried out by Regulatory Authorities (RA) (e.g. Swissmedic, FOPH) to ensure that market-approved products comply with applicable laws and regulations.

 

Regulatory Authorities (RA) (e.g. Swissmedic):

  • Are responsible for monitoring the safety of therapeutic products placed on the market. They monitor whether the manufacturing, distribution, dispensing and maintenance of, and claims relating to therapeutic products are lawful

 

RAs entrusted with the implementation of the TPA act may:

  • Take samples
  • Request essential information and documents

 

In order to increase market surveillance efficiency, the Swiss cantons work in close collaboration with RAs (e.g. Swissmedic, FOPH). Cantons notify RAs of any unexpected events, potential safety findings, or public complaints.

In order to protect the public, RAs are responsible to implement applicable administrative measures. In the event of a serious direct threat to health, Cantons may also be asked to implement required administrative measures.

What do I need to do?

As a SP-INV get familiar with the definition of market surveillance.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissmedic – see in particular

  • Human medicines / market surveillance for medicinal products
  • Medical devices / market surveillance of medical devices

FOPH – see in particular

  • Strategy & Policy / National health strategies
  • Monitoring in the FOPH / Overview of monitorings and surveillances

Swiss Law

TPA – see in particular articles an section

  • Art. 4 Definition placing on the market
  • Section 3: Market surveillance and inspection procedures
  • Art. 58 Official market surveillance

MedDO – see in particular

  • Chapter 7 Device surveillance
Abbreviations
  • CTU – Clinical Trials Unit
  • FOPH – Federal Office of Public Health
  • MedDO – Medical Devices Ordinance
  • RA – Regulatory Authorities
  • SP-INV – Sponsor Investigator
  • TPA – Therapeutic Product Act
Basic ↦ Drug or Device ↦ Therapeutic Products ↦ Market Surveillance
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Drug or Device ↦ Therapeutic Products ↦ Market Surveillance

Please note: the Easy-GCS tool is currently under construction.